CXCL13: a mediator of prostate cancer progression
CXCL13: a mediator of prostate cancer progression
批准号:
9256445
负责人:
MARCELO G. KAZANIETZ
金额:
$35.61万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-01 至 2020-03-31
关键词:
AnimalsAntineoplastic AgentsAttentionAutomobile DrivingBLR1 geneBioinformaticsBreastCXCL13 geneCancer EtiologyCarcinomaCell modelCellsCessation of lifeCollectionDataDevelopmentDiglyceridesDiseaseDisease ProgressionDrug TargetingEngineeringEpithelialEpithelial CellsEtiologyEventGene Expression ProfileGenesGrowthGuanine Nucleotide Exchange FactorsHead and Neck CancerHumanHuman CharacteristicsImmunocompetentImpairmentIn VitroIndividualInjection of therapeutic agentKnock-outKnockout MiceLaboratoriesLesionLungLymphocyte DepletionMaintenanceMalignant NeoplasmsMalignant neoplasm of prostateMediatingMediator of activation proteinMessenger RNAMetastatic Prostate CancerMicroarray AnalysisModelingMolecularMonomeric GTP-Binding ProteinsMusNeoplasm MetastasisNude MiceOncogenicPIK3CG genePathologyPathway interactionsPharmacologyPhenotypePhosphoric Monoester HydrolasesPhosphotransferasesPlayProductionProliferatingPropertyProstateProstate AdenocarcinomaProstatic NeoplasmsProtein IsoformsProtein Microarray AssayProtein OverexpressionRNA InterferenceRecurrenceRoleSignal PathwaySignal TransductionSiteSpecimenStimulation of Cell ProliferationSubfamily lentivirinaeTherapeuticTransgenic MiceTransgenic ModelTransgenic OrganismsTumor Suppressor ProteinsTumorigenicityUp-Regulationautocrinebonecancer biomarkerscancer therapycell motilitycell transformationcellular engineeringchemokinedrug developmentgrasplink proteinmenmouse modelnoveloverexpressionprognosticprostate cancer cellprostate cancer cell lineprostate carcinogenesisprotein kinase C epsilonpublic health relevancerac GTP-Binding Proteinsreceptorsmall hairpin RNAtumortumor progressiontumorigenesistumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Prostate cancer is the second leading cause of cancer-related deaths among men in the US. A large body of evidence links protein kinase C epsilon (PKC) to cancer progression. PKC is markedly up-regulated in epithelial cancers, including prostate cancer, potentially reflecting its involvement in the etiology and progression o the disease. We found that prostate-specific PKC transgenic mice (PB-PKC) develop preneoplastic lesions (PINs), and remarkably, they develop invasive prostatic adenocarcinomas in a Pten haplodeficient background. Understanding the molecular basis of this cooperativity is highly relevant, as loss of the tumor suppressor Pten, a negative regulator of the PI3K pathway, is a common alteration of prostate cancer. We generated a number of cellular models recapitulating PKC overexpression and Pten loss, which display enhanced growth, motility, and invasiveness in vitro, and acquire tumorigenic potential in nude mice. Moreover, gene profiling and bioinformatics analysis revealed that PKC overexpressing/Pten depleted cells display a pattern of gene expression distinctive of human metastatic prostate cancer. We found that the "top hit" in this microarray analysis is the chemokine CXCL13. Notably, PKC cooperates with Pten loss to strongly induce CXCL13 mRNA levels and its release, and RNAi depletion of CXCL13 or its receptor (CXCR5) impairs the ability of PKC overexpressing/Pten-deficient cells to proliferate and migrate. Preliminary data also suggest that PKC and PI3K are downstream effectors of CXCR5, suggesting a positive amplification loop that may act as a vicious cycle. In Specific Aim 1, we will establish the relevance of the CXCL13:CXCR5 axis in prostate tumorigenesis using an inducible silencing approach. A potential contribution of stromal CXCL13 will be examined using immunocompetent mice and depletion of lymphocytes involved in CXCL13 production. In addition, knock-out CXCL13 and CXCR5 mice will be crossed with PB- PKC mice as an approach to assess the requirement of the CXCL13:CXCR5 axis in the development of prostate lesions and the activation of key mitogenic/survival pathways. In Specific Aim 2, we will examine the role of CXCL13:CXCR5 in metastasis using intraprostatic injections and also assess the role of this pathway in metastatic dissemination to bone. Mechanistic studies will be pursued to explore the potential relevance of Rac, a small G-protein, and its exchange factors (Rac-GEFs) in the motile/invasive phenotype driven by the PKC-PI3K-CXCL13-CXCR5 pathway. In Specific Aim 3, we will focus on the mechanisms involved in CXCL13 induction by PKC and PI3K, specifically dissecting the roles of Akt, Erk, Stat3, NF-B and specific p110 PI3Ks in controlling CXCL13 production. We will also investigate PKC as a potential CXCR5 downstream effector. Lastly, in Specific Aim 4 we will establish the relevance of the PKC/Pten-CXCL13 association in human prostate tumors using a large collection of prostate cancer specimens, and assess correlations with disease progression and recurrence. In addition to the mechanistic implications, the proposed studies may have major prognostic and therapeutic impact for personalized prostate cancer treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protein kinase C signaling in prostate cancer health disparities
-
批准号:10744533
-
项目类别:
-
资助金额:$48.8万
-
财政年份:2023
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Effectors of protein kinase C-mediated tumor progression
-
批准号:10543367
-
项目类别:
-
资助金额:$3.55万
-
财政年份:2022
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Rac guanine nucleotide exchange factors in lung cancer
-
批准号:10522390
-
项目类别:
-
资助金额:$47.05万
-
财政年份:2022
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Rac guanine nucleotide exchange factors in lung cancer
-
批准号:10674846
-
项目类别:
-
资助金额:$46.11万
-
财政年份:2022
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Effectors of protein kinase C-mediated tumor progression
-
批准号:9198206
-
项目类别:
-
资助金额:$38.97万
-
财政年份:2016
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Effectors of protein kinase C-mediated tumor progression
-
批准号:9042748
-
项目类别:
-
资助金额:$38.97万
-
财政年份:2016
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Protein kinase C and lung carcinogenesis
-
批准号:9126982
-
项目类别:
-
资助金额:$39.12万
-
财政年份:2015
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
ErbB receptor signaling via small G-proteins in breast cancer
-
批准号:8468659
-
项目类别:
-
资助金额:$35.16万
-
财政年份:2010
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
ErbB receptor signaling via small G-proteins in breast cancer
-
批准号:8607903
-
项目类别:
-
资助金额:$36.99万
-
财政年份:2010
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
ErbB receptor signaling via small G-proteins in breast cancer
-
批准号:8062243
-
项目类别:
-
资助金额:$30.61万
-
财政年份:2010
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
ErbB receptor signaling via small G-proteins in breast cancer
-
批准号:7783613
-
项目类别:
-
资助金额:$36.19万
-
财政年份:2010
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
ErbB receptor signaling via small G-proteins in breast cancer
-
批准号:8264782
-
项目类别:
-
资助金额:$36.7万
-
财政年份:2010
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Heregulin signaling via small GTPases in mitogenesis and tumorigenesis
-
批准号:7858442
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2009
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Heregulin signaling via small GTPases in mitogenesis and tumorigenesis
-
批准号:7582161
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2009
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Prostate Carcinogensis and PKC Signaling
-
批准号:6522750
-
项目类别:
-
资助金额:$28.53万
-
财政年份:2001
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Prostate carcinogenesis and PKC signaling
-
批准号:8205860
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2001
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Prostate carcinogenesis and PKC signaling
-
批准号:7738251
-
项目类别:
-
资助金额:$31.45万
-
财政年份:2001
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Prostate Carcinogensis and PKC Signaling
-
批准号:6654826
-
项目类别:
-
资助金额:$28.53万
-
财政年份:2001
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Prostate carcinogenesis and PKC signaling
-
批准号:8682789
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2001
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
Prostate carcinogenesis and PKC signaling
-
批准号:8321980
-
项目类别:
-
资助金额:$32.78万
-
财政年份:2001
-
负责人:MARCELO G. KAZANIETZ
-
依托单位:
海外基金